Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Importance of Managing Nausea Related to T-DXd in HR+ Breast Cancer

January 7, 2024
By Sarah Donahue, MPH, NP
Commentary
Video

Sarah Donahue, MPH, NP, discusses her strategy for administering doxorubicin, cyclophosphamide, and antiemetics to manage nausea following trastuzumab deruxtecan therapy for patients with hormone receptor–positive breast cancer.

Managing nausea related to treatment with trastuzumab deruxtecan (T-DXd; Enhertu) for patients with hormone receptor–positive breast cancer is important to reducing fatigue and improve quality of life, according to Sarah Donahue, MPH, NP.

Donahue, a nurse practitioner at University of California, San Francisco, and part of the Oncology Nursing Society, spoke with CancerNetwork® about her strategies for mitigating the effects of nausea among patients at her practice. According to Donahue, she uses pre-medications such as doxorubicin and cyclophosphamide as well as other agents including olanzapine to the limit the amount of nausea that may follow treatment with T-DXd.

Transcript:

With T-DXd, many of my patients with hormone receptor–positive, HER2-negative or HER2-low metastatic breast cancer would qualify for this, and many of them have never had a medication, like T-DXd before. T-DXd can cause cardiovascular effects.

The other main [adverse] effect of that medication is mostly nausea. It’s pretty common. You’re giving a lot of pre-medications. You’re giving doxorubicin and cyclophosphamide; you’re giving them the works. And then you’re making sure that at home they have the antiemetics to use as needed. Sometimes, in the first cycle, I’ll help patients schedule it because it’s harder to catch up with the pain. I don’t want to create a situation where every time they’re coming in, they’re thinking about the nausea that they had last time, [feeling] worried, and having that anticipatory nausea, as well. I give them a lot of these medications to take at home with a little bit of scheduling.

What I found is that some of these patients will have a nausea that occurs for longer than you would expect with a medication. What I find is adding on olanzapine at bedtime for the first 3 to 5 nights starting the night of treatment really helps. Sometimes I have patients who just continue with that even longer or take it as needed, and they are needing it later on. When we’re talking about the patient’s quality of life, if they’re not eating well and they’re nauseated, they’re going to have some level of fatigue, low blood sugar, and lack of hydration because they’re not feeling well enough to drink. A lot of my goals to make them feel as normal as possible and having the least amount of fatigue so that they can do what they want to be doing—which makes them feel better emotionally, too—are really targeting that nausea and making sure that it is very well controlled.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Advertisement

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer

Russ Conroy
September 25th 2025
Article

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

ONCOLOGY Staff
September 23rd 2025
Article

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 9th 2025
Article

THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.


Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Trastuzumab Pamirtecan Improves PFS in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
September 7th 2025
Article

Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Related Content
Advertisement

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer

Russ Conroy
September 25th 2025
Article

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

ONCOLOGY Staff
September 23rd 2025
Article

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 9th 2025
Article

THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.


Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Trastuzumab Pamirtecan Improves PFS in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
September 7th 2025
Article

Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.